CN113316471A - 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式 - Google Patents

7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式 Download PDF

Info

Publication number
CN113316471A
CN113316471A CN202080009222.3A CN202080009222A CN113316471A CN 113316471 A CN113316471 A CN 113316471A CN 202080009222 A CN202080009222 A CN 202080009222A CN 113316471 A CN113316471 A CN 113316471A
Authority
CN
China
Prior art keywords
modification
ribociclib
crystalline form
salt
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080009222.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·格兰德瑞
N·帕特尔
F·舍费尔
D·齐默尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113316471A publication Critical patent/CN113316471A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080009222.3A 2019-01-23 2020-01-23 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式 Pending CN113316471A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795799P 2019-01-23 2019-01-23
US62/795,799 2019-01-23
PCT/IB2020/050544 WO2020152629A1 (en) 2019-01-23 2020-01-23 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Publications (1)

Publication Number Publication Date
CN113316471A true CN113316471A (zh) 2021-08-27

Family

ID=69467591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080009222.3A Pending CN113316471A (zh) 2019-01-23 2020-01-23 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式

Country Status (8)

Country Link
US (2) US12390468B2 (cg-RX-API-DMAC10.html)
EP (1) EP3914353A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022517842A (cg-RX-API-DMAC10.html)
CN (1) CN113316471A (cg-RX-API-DMAC10.html)
AU (2) AU2020211071A1 (cg-RX-API-DMAC10.html)
CA (1) CA3124015A1 (cg-RX-API-DMAC10.html)
IL (1) IL284510B2 (cg-RX-API-DMAC10.html)
WO (1) WO2020152629A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002123A (es) 2017-08-25 2020-09-18 Sicor Soc It Corticosteroidi S R L Sales de ribociclib y formas en estado sólido de las mismas.
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
EP4762058A1 (en) * 2023-08-18 2026-06-24 Alembic Pharmaceuticals Limited Polymorph of ribociclib salt
WO2025144118A1 (en) * 2023-12-27 2025-07-03 Deva Holding Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation
US20250319032A1 (en) 2024-04-15 2025-10-16 Novartis Ag Pharmaceutical compositions of ribociclib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201275A (zh) * 2010-11-10 2013-07-10 诺华有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺的盐及其制备方法
CN105085533A (zh) * 2014-12-12 2015-11-25 苏州晶云药物科技有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺单琥珀酸盐的新晶型
US20180282342A1 (en) * 2014-12-12 2018-10-04 Crystal Pharmatech Co., Ltd. Salt of Pyrrolo[2,3-D]pyrimidine Compound and Novel Polymorph of Salt

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
EA012926B1 (ru) 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
BRPI0612997A2 (pt) 2005-07-22 2010-12-14 Qualcomm Incorporated dispositivos mems e respectivos mÉtodos de fabrico
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
ES2910444T3 (es) 2012-02-24 2022-05-12 Nokia Technologies Oy Método y aparato para establecer una conexión con una red de acceso basándose en información de interfuncionamiento de red de acceso
WO2016091221A1 (zh) 2014-12-12 2016-06-16 苏州晶云药物科技有限公司 吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
US10323035B2 (en) 2015-04-01 2019-06-18 Crystal Pharmatech Co., Ltd. Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
MX2020002123A (es) 2017-08-25 2020-09-18 Sicor Soc It Corticosteroidi S R L Sales de ribociclib y formas en estado sólido de las mismas.
WO2019111160A1 (en) 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate
WO2019123364A1 (en) 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
WO2019142206A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited An improved process for the preparation of ribociclib succinate and its novel crystalline forms thereof
TWI675662B (zh) * 2018-05-17 2019-11-01 中化合成生技股份有限公司 瑞博西尼琥珀酸鹽(Ribociclib succinate salt)晶型B、C及D與其衍生物,以及其等之製造方法與藥物組合物
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201275A (zh) * 2010-11-10 2013-07-10 诺华有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺的盐及其制备方法
CN105399743A (zh) * 2010-11-10 2016-03-16 诺华有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺的盐及其制备方法
CN105085533A (zh) * 2014-12-12 2015-11-25 苏州晶云药物科技有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺单琥珀酸盐的新晶型
US20180282342A1 (en) * 2014-12-12 2018-10-04 Crystal Pharmatech Co., Ltd. Salt of Pyrrolo[2,3-D]pyrimidine Compound and Novel Polymorph of Salt

Also Published As

Publication number Publication date
CA3124015A1 (en) 2020-07-30
EP3914353A1 (en) 2021-12-01
AU2023200724A1 (en) 2023-03-09
US20230042479A1 (en) 2023-02-09
JP2024099797A (ja) 2024-07-25
US12390468B2 (en) 2025-08-19
US20250281492A1 (en) 2025-09-11
AU2023200724B2 (en) 2025-01-23
WO2020152629A1 (en) 2020-07-30
KR20210119444A (ko) 2021-10-05
IL284510A (en) 2021-08-31
IL284510B1 (en) 2025-06-01
AU2020211071A1 (en) 2021-07-15
JP2022517842A (ja) 2022-03-10
IL284510B2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
AU2023200724B2 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
JP7320741B2 (ja) B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP6918824B2 (ja) 2−[(2S)−1−アザビシクロ[2.2.2]オクタ−2−イル]−6−(3−メチル−1H−ピラゾール−4−イル)チエノ[3,2−d]ピリミジン−4(3H)−オン半水和物の結晶形
JP2024037930A (ja) Tlr7/tlr8阻害剤の結晶形態
JPH11509865A (ja) 5―(2―(4―(1,2―ベンズイソチアゾール―3―イル)―1―ピペラジニル)エチル)―6―クロロ―1,3―ジヒドロ―2(1h)―インドール―2―オン(=ジプラシドン)のメシレート三水和物、その調製法およびドーパミンd2アンタゴニストとしてのその使用法
CN105164105A (zh) 吡咯衍生物的结晶及其制备方法
JP7682923B2 (ja) ゲポチダシンの結晶形態
JP2025538506A (ja) がんの治療のための縮合ピリジンの固体形態
EP3183253A1 (en) Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
WO2007109799A2 (en) Polymorphs of eszopiclone malate
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
KR20250155619A (ko) 결정질 형태
KR20210024004A (ko) Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
WO2025241792A1 (zh) 艾拉司群二盐酸盐的新晶型及其制备方法和用途
RU2857779C2 (ru) Новые кристаллические формы сукцинатной соли диметиламида 7-циклопентил-2-(5-пиперазин-1-илпиридин-2-иламино)-7h-пирроло[2,3-d]пиримидин-6-карбоновой кислоты
EP3645535A1 (en) New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it
CN101353343A (zh) 高纯度盐酸诺拉曲塞二水合物的制备方法
TW202613137A (zh) 新晶型
WO2026067446A1 (zh) 一种大稠环化合物的盐、多晶型物及其应用
WO2025223554A1 (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
KR20240146734A (ko) 피마살탄의 신규 염 및 이의 제조방법
JP2008528690A (ja) 結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用
TW202604502A (zh) Shp2抑制劑的新的晶型及其用途
WO2025203051A1 (en) Ribociclib succinate form c and process thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination